Celiac Disease

Microbiome Signature#

Celiac disease is associated with a characteristic gut Dysbiosis documented in both active disease and treated (GFD-adherent) patients:

Depleted. Bifidobacterium (especially B. longum and B. adolescentis)—consistently reduced across paediatric and adult cohorts (Collado et al. 2009; De Palma et al. 2010; Golfetto et al.

2014).

Lactobacillus—reduced luminal and mucosal populations, correlating with impaired gluten peptide degradation. Faecalibacterium prausnitzii and other Lachnospiraceae—Butyrate producers whose loss worsens epithelial energy deficit in the setting of villous atrophy. Prevotella spp.—depleted in active disease.

Enriched. Proteobacteria (Pseudomonadota) at phylum level (a consistent dysbiosis marker). Escherichia coli—some strains express proteolytic activity that enhances rather than reduces gliadin immunogenicity (Caminero et al. 2019, Gastroenterology). Staphylococcus spp.

Bacteroides fragilis—elevated proteolytic strains that deamidate gliadin peptides similarly to tTG2, priming HLA-DQ2 presentation.

Mechanistic bridge: Caminero et al. (2016, Gut) showed that lactobacilli from healthy subjects fully degrade the immunogenic 33-mer gliadin peptide, while pseudomonal and E. coli proteases from celiac patients only partially cleave it, generating residual epitopes that remain antigenic.

This establishes the microbiome as a checkpoint on gluten immunogenicity rather than a passive observer. Wheat-associated Pseudomonas aeruginosa specifically produces elastase-like proteases that generate more, not fewer, HLA-DQ2-binding peptides.

This dysbiosis pattern overlaps substantially with other conditions in this knowledge base, suggesting shared metal-microbiome mechanisms may operate in celiac disease beyond the primary gluten-immune axis.

Metabolomic Signature#

Short-chain fatty acids (butyrate, propionate, acetate)—reduced due to depletion of SCFA-producing Faecalibacterium and Lachnospiraceae; compounds epithelial repair deficit.

Tryptophan metabolites—altered indole/AhR ligand production due to loss of Lactobacillus reuteri and related species, impairing AhR (Aryl Hydrocarbon Receptor) signalling and Treg induction (Lamas et al. 2016).

Bile acids—secondary bile acid profile shifted in treated celiac patients (Wacklin et al. 2014), with implications for FXR-mediated intestinal barrier regulation. Zonulin—elevated serum levels signal active tight-junction disassembly; a biomarker of the "leaky gut" phase of celiac pathogenesis.

Associated Conditions and Shared Signatures#

Celiac disease shares serological, genetic, and microbial patterns with several other conditions. Type 1 Diabetes—shared HLA-DQ2/DQ8 risk haplotypes; ~8% of T1D patients carry celiac antibodies. Both conditions feature early-life Bifidobacterium depletion and altered mucosal tolerance.

Hashimoto's Thyroiditis—~4-5x increased prevalence of celiac among autoimmune thyroid patients; shared selenium and iron malabsorption may worsen thyroid hormone synthesis. Dermatitis Herpetiformis—essentially cutaneous celiac disease; IgA anti-tTG deposits in skin. Most DH patients have some degree of villous atrophy.

Irritable Bowel Syndrome (IBS)—overlapping symptoms create diagnostic ambiguity; a subset of "IBS" patients are misdiagnosed celiacs and vice versa. Both show Bifidobacterium and Faecalibacterium depletion.

Inflammatory Bowel Disease (IBD)—modest bidirectional association; shared features include increased intestinal permeability and Proteobacteria bloom. Non-celiac gluten sensitivity (NCGS)—distinct from celiac but symptomatically overlapping; microbiome signatures intermediate between celiac and healthy controls.